India’s first indigenous Covid-19 vaccine, Covaxin, developed by Bharat Biotech in association with the Indian Council of Medical Research, has been shown to be “well tolerated across all dose groups, with no serious vaccine-related adverse events” , according to interim results from the Phase 1 trial of Covaxin.
- “Moral bankruptcy”: a whistleblower offers a scathing assessment of Facebook | Facebook
- Mally Mall files for bankruptcy in jail: report
- NCLT clears bankruptcy proceedings against former promoters of Bhushan Power and Steel
- Legislation on the reform of bankruptcy sites Back; Previous efforts have been blocked